Skip to main
TVGN

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings is expected to release its first clinical product, TVGN 489, which is initially focused on treating COVID-19 in high-risk populations, but also has potential applications in treating chronic symptoms of the disease (Long COVID). Additionally, the company's potential acquisition of a contract research organization could improve earnings visibility and support a more efficient growth strategy. However, there are risks to consider, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks.

Bears say

Tevogen Bio Holdings is facing multiple risk factors, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks. With potential dilution risk due to a large decrease in stock price and pushing back the timeline for commercialization to 2029, it is understandable that the financial analyst has a negative outlook and has lowered the price target to $2.0 from $5.0. In addition, the company has a high accumulated deficit and operating losses, indicating potential financial instability in the future, despite efforts to improve cost efficiency.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.